Skip to main content
SpringerLink
Log in
Book cover

Male LUTS/BPH Made Easy pp 67–87Cite as

Medical Treatment of LUTS/BPH

  • Chapter
  • First Online:

Abstract

Several drug therapies are available for male patients with bothersome lower urinary tract symptoms. Monotherapy with α-blockers is a commonly used and effective treatment to quickly improve LUTS, quality of life, and Q max. The main differences among the drugs are in the profile of adverse events [AEs], with cardiovascular AEs less prevalent with uroselective drugs (and especially with the novel silodosin, which is the compound with the highest selectivity). Conversely, ejaculatory dysfunction is less prevalent with nonselective drugs. 5α-reductase inhibitors [5-ARIs], alone or in combination with α-blockers, might be offered to men who have moderate to severe LUTS and an enlarged prostate to reduce the risk of urinary retention and prostate-related surgery. Those patients with prevalent storage LUTS may have benefited from anticholinergics. The risk of urinary retention with that category of drugs is minimal if patients with a higher risk of bladder outlet obstruction are avoided (e.g., those with PVR >200 mL, Q max <5 mL/s, or history of prior retention). Finally, tadalafil 5 mg is effective in improving symptoms in patients with LUTS, with or without concomitant erectile dysfunction.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Oelke M, Bachmann A, Descazeaud M, Emberton S, Gravas MC, Michel J, N’Dow J, Nordling JJ de la Rosette. Guidelines on the management of male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). Available from: http://www.uroweb.org/gls/pdf/12_Male_LUTS_after.corrections.pdf.

  2. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–803.

    Article  PubMed  Google Scholar 

  3. National Institute for Health and Clinical Excellence guidelines. The management of lower urinary tract symptoms in men. Available from: http://guidance.nice.org.uk/CG97/NICEGuidance/pdf/English.

  4. Brown CT, Yap T, Cromwell DA, Rixon L, Steed L, Mulligan K, et al. Self management for men with lower urinary tract symptoms: randomised controlled trial. BMJ. 2007;334(7583):25. PubMed PMID: 17118949. Pubmed Central PMCID: 1764065.

    Article  PubMed  Google Scholar 

  5. Cornu JN, Cussenot O, Haab F, Lukacs B. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur Urol. 2010;58(3):450–6. PubMed PMID: 20554374.

    Article  PubMed  Google Scholar 

  6. Schilit S, Benzeroual KE. Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia. Clin Ther. 2009;31(11):2489–502. PubMed PMID: 20109995. Epub 2010/01/30. eng.

    Article  PubMed  CAS  Google Scholar 

  7. Wilt TJ, Howe RW, Rutks IR, MacDonald R. Terazosin for benign prostatic hyperplasia. Cochrane Database Syst Rev (Online). 2002;(4):CD003851. PubMed PMID: 12519611. Epub 2003/01/10. eng.

    Google Scholar 

  8. Wilt TJ, Mac Donald R, Rutks I. Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev (Online). 2003;(1):CD002081. PubMed PMID: 12535426. Epub 2003/01/22. eng.

    Google Scholar 

  9. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009;181(6):2634–40. PubMed PMID: 19371887. Epub 2009/04/18. eng.

    Article  PubMed  CAS  Google Scholar 

  10. Kawabe K, Yoshida M, Homma Y, Silodosin Clinical Study G. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006;98(5):1019–24.

    Article  PubMed  CAS  Google Scholar 

  11. Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernandez Fernandez E, et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011;59(3):342–52. PubMed PMID: 21109344.

    Article  PubMed  CAS  Google Scholar 

  12. Novara G, Tubaro A, Sanseverino R, Spatafora S, Artibani W, Zattoni F, et al. Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement. World J Urol. 2013;31(4):997–1008. PubMed PMID: 23053207. Epub 2012/10/12. Eng.

    Google Scholar 

  13. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992;327(17):1185–91. PubMed PMID: 1383816. Epub 1992/10/22. eng.

    Article  PubMed  CAS  Google Scholar 

  14. Tenover JL, Pagano GA, Morton AS, Liss CL, Byrnes CA. Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigator Study Group. Clin Ther. 1997;19(2):243–58. PubMed PMID: 9152564. Epub 1997/03/01. eng.

    Article  PubMed  CAS  Google Scholar 

  15. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group. Prostate. 1993;22(4):291–9. PubMed PMID: 7684524. Epub 1993/01/01. eng.

    Google Scholar 

  16. Byrnes CA, Morton AS, Liss CL, Lippert MC, Gillenwater JY. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar. Clin Ther. 1995;17(5):956–69. PubMed PMID: 8595647. Epub 1995/09/01. eng.

    Article  PubMed  CAS  Google Scholar 

  17. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338(9):557–63. PubMed PMID: 9475762. Epub 1998/02/26. eng.

    Article  PubMed  CAS  Google Scholar 

  18. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G, Aria A, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60(3):434–41. PubMed PMID: 12350480.

    Article  PubMed  Google Scholar 

  19. Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ. Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev (Online). 2010 (10):CD006015. PubMed PMID: 20927745. Epub 2010/10/12. eng.

    Google Scholar 

  20. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med. 1996;335(8):533–9. PubMed PMID: 8684407. Epub 1996/08/22. eng.

    Article  PubMed  CAS  Google Scholar 

  21. Debruyne FM, Jardin A, Colloi D, Resel L, Witjes WP, Delauche-Cavallier MC, et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol. 1998;34(3):169–75. PubMed PMID: 9732187. Epub 1998/09/10. eng.

    Article  PubMed  CAS  Google Scholar 

  22. Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003;61(1):119–26. PubMed PMID: 12559281. Epub 2003/02/01. eng.

    Article  PubMed  Google Scholar 

  23. McConnell JD, Roehrborn CG, Bautista OM, Andriole Jr GL, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–98. PubMed PMID: 14681504.

    Article  PubMed  CAS  Google Scholar 

  24. Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006;175(4):1422–6; discussion 6–7. PubMed PMID: 16516013.

    Article  PubMed  CAS  Google Scholar 

  25. Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol. 2006;175(1):217–20; discussion 20–1. PubMed PMID: 16406915.

    Article  PubMed  CAS  Google Scholar 

  26. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–31. PubMed PMID: 19825505.

    Article  PubMed  Google Scholar 

  27. Novara G, Galfano A, Secco S, D’Elia C, Cavalleri S, Ficarra V, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 2008;54(4):740–63. PubMed PMID: 18632201. Epub 2008/07/18. eng.

    Article  PubMed  CAS  Google Scholar 

  28. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296(19):2319–28. PubMed PMID: 17105794. Epub 2006/11/16. eng.

    Article  PubMed  CAS  Google Scholar 

  29. Van Kerrebroeck P, Haab F, Angulo JC, Vik V, Katona F, Garcia-Hernandez A, Klaver M, Traudtner K, Oelke M. Efficacy and safety of solifenacin pl 1 us tamsulosin OCAS™ in men with LUTS associated with BPH: results from a phase 2, dose-finding study (SATURN). Eur Urol. 2013;64(3):398–407.

    Article  PubMed  Google Scholar 

  30. Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol. 2009;56(3):534–41. PubMed PMID: 19070418. Epub 2008/12/17. eng.

    Article  PubMed  CAS  Google Scholar 

  31. Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol. 2013;189(1 Suppl):S129–34. PubMed PMID: 23234618. Epub 2012/12/19. eng.

    Article  PubMed  CAS  Google Scholar 

  32. Geavlete P, Multescu R, Geavlete B. Serenoa repens extract in the treatment of benign prostatic hyperplasia. Ther Adv Urol. 2011;3(4):193–8. PubMed PMID: 21969849. Pubmed Central PMCID: PMC3175703. Epub 2011/10/05. eng.

    Article  PubMed  Google Scholar 

  33. Tacklind J, MacDonald R, Rutks I, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev (Online). 2009; (2):CD001423. PubMed PMID: 19370565. Pubmed Central PMCID: PMC3090655. Epub 2009/04/17. eng.

    Google Scholar 

  34. Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011;306(12):1344–51. PubMed PMID: 21954478. Pubmed Central PMCID: 3326341.

    Article  PubMed  CAS  Google Scholar 

  35. Habib FK, Wyllie MG. Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis. 2004;7(3):195–200.

    Article  PubMed  CAS  Google Scholar 

  36. Scaglione F, Lucini V, Pannacci M, Caronno A, Leone C. Comparison of the potency of different brands of Serenoa repens extract on 5alpha-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells. Pharmacology. 2008;82(4):270–5.

    Article  PubMed  CAS  Google Scholar 

  37. Glemain P, Coulange C, Billebaud T, Gattegno B, Muszynski R, Loeb G. Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial. Prog Urol. 2002;12(3):395–403; discussion 4. PubMed PMID: 12189745. Epub 2002/08/23. Tamsulosine avec ou sans Serenoa repens dans l’hypertrophie benigne de la prostate: l’essai OCOS. fre.

    PubMed  Google Scholar 

  38. Hizli F, Uygur MC. A prospective study of the efficacy of Serenoa repens, Tamsulosin, and Serenoa repens plus Tamsulosin treatment for patients with benign prostate hyperplasia. Int Urol Nephrol. 2007;39(3):879–86.

    Article  PubMed  CAS  Google Scholar 

  39. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44(6):637–49. PubMed PMID: 14644114.

    Article  PubMed  Google Scholar 

  40. Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurouroluro dynamics. 2011;30(3):292–301. PubMed PMID: 21284024. Epub 2011/02/02. eng.

    CAS  Google Scholar 

  41. McVary KT, Kaufman J, Young JM, Tseng LJ. Sildenafil citrate improves erectile function: a randomised double-blind trial with open-label extension. Int J Clin Pract. 2007;61(11):1843–9. PubMed PMID: 17887993. Epub 2007/09/25. eng.

    Article  PubMed  CAS  Google Scholar 

  42. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002;90(9):836–9. PubMed PMID: 12460342. Epub 2002/12/04. eng.

    Article  PubMed  CAS  Google Scholar 

  43. Martinez-Salamanca JI, Carballido J, Eardley I, Giuliano F, Gratzke C, Rosen R, et al. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence. Eur Urol. 2011;60(3):527–35. PubMed PMID: 21684677. Epub 2011/06/21. eng.

    Article  PubMed  CAS  Google Scholar 

  44. Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61(5):994–1003. PubMed PMID: 22405510. Epub 2012/03/13. eng.

    Article  PubMed  CAS  Google Scholar 

  45. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008;53(6):1236–44. PubMed PMID: 18281145. Epub 2008/02/19. eng.

    Article  PubMed  CAS  Google Scholar 

  46. Hatzimouratidis K, Hatzichristou DG. Looking to the future for erectile dysfunction therapies. Drugs. 2008;68(2):231–50. PubMed PMID: 18197727.

    Article  PubMed  CAS  Google Scholar 

  47. Wrishko R, Sorsaburu S, Wong D, Strawbridge A, McGill J. Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil. J Sex Med. 2009;6(7):2039–48. PubMed PMID: 19453893. Epub 2009/05/21. eng.

    Article  PubMed  CAS  Google Scholar 

  48. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007;177(4):1401–7. PubMed PMID: 17382741. Epub 2007/03/27. eng.

    Article  PubMed  CAS  Google Scholar 

  49. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urology. 2008;180(4):1228–34. PubMed PMID: 18722631. Epub 2008/08/30. eng.

    Article  CAS  Google Scholar 

  50. Porst H, Kim ED, Casabe AR, Mirone V, Secrest RJ, Xu L, et al. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol. 2011;60(5):1105–13. PubMed PMID: 21871706. Epub 2011/08/30. eng.

    Article  PubMed  CAS  Google Scholar 

  51. Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012;61(5):917–25. PubMed PMID: 22297243. Epub 2012/02/03. eng.

    Article  PubMed  CAS  Google Scholar 

  52. Liu L, Zheng S, Han P, Wei Q. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Urology. 2011;77(1):123–9. PubMed PMID: 21195830.

    Article  PubMed  Google Scholar 

  53. Liguori G, Trombetta C, De Giorgi G, Pomara G, Maio G, Vecchio D, et al. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. J Sex Med. 2009;6(2):544–52. PubMed PMID: 19138360. Epub 2009/01/14. eng.

    Article  PubMed  CAS  Google Scholar 

  54. Bechara A, Romano S, Casabe A, Haime S, Dedola P, Hernandez C, et al. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med. 2008;5(9):2170–8. PubMed PMID: 18638006. Epub 2008/07/22. eng.

    Article  PubMed  CAS  Google Scholar 

  55. Mangera A, Andersson KE, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol. 2011;60(4):784–95. PubMed PMID: 21782318.

    Article  PubMed  CAS  Google Scholar 

  56. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology. 2003;62(2):259–64; discussion 64–5. PubMed PMID: 12893330.

    Article  PubMed  Google Scholar 

  57. Marberger M, Chartier-Kastler E, Egerdie B, Lee KS, Grosse J, Bugarin D, et al. A randomized double-blind placebo-controlled phase 2 dose-ranging study of OnabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol. 2013;63(3):496–503. PubMed PMID: 23098762.

    Article  PubMed  CAS  Google Scholar 

  58. Aizawa N, Homma Y, Igawa Y. Effects of mirabegron, a novel beta3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol. 2012;62(6):1165–73. PubMed PMID: 22981677. Epub 2012/09/18. eng.

    Article  PubMed  CAS  Google Scholar 

  59. Khullar V, Amarenco G, Angulo JC, Cambronero J, Hoye K, Milsom I, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283–95. PubMed PMID: 23182126.

    Article  PubMed  CAS  Google Scholar 

  60. Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305. PubMed PMID: 23195283.

    Article  PubMed  CAS  Google Scholar 

  61. Ventura S, Oliver VL, White CW, Xie JH, Haynes JM, Exintaris B. Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). Br J Pharmacol. 2011;163(5):891–907.

    Article  PubMed  CAS  Google Scholar 

  62. Hashim H, Abrams P. Emerging drugs for the treatment of benign prostatic obstruction. Expert Opin Emerg Drugs. 2010;15(2):159–74.

    Article  PubMed  CAS  Google Scholar 

  63. Shore N. NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs. 2010;19(2):305–10.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncological and Surgical Sciences, Urology Clinic, University of Padua, Via Giustiniani 2, Padua, 35100, Italy

    Giacomo Novara, Vincenzo Ficarra & Filiberto Zattoni

Authors
  1. Giacomo Novara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vincenzo Ficarra
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Filiberto Zattoni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giacomo Novara .

Editor information

Editors and Affiliations

  1. Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust The Royal Hallamshire Hospital, Sheffield, United Kingdom

    Christopher R. Chapple

  2. Department of Urology, Sant'Andrea Hospital, Rome, Italy

    Andrea Tubaro

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Novara, G., Ficarra, V., Zattoni, F. (2014). Medical Treatment of LUTS/BPH. In: Chapple, C., Tubaro, A. (eds) Male LUTS/BPH Made Easy. Springer, London. https://doi.org/10.1007/978-1-4471-4688-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4688-9_5

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4687-2

  • Online ISBN: 978-1-4471-4688-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation